Zymeworks reports trial results for ovarian cancer drug ZW191
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $ZYME -0.77% in the latest session.
- Timing: Weekend news: the change beside it is Friday's, and Monday's open is the first session that gets a say. Market holidays are not detected.
Where the stock stands
$ZYME last changed hands at $28.22, -0.77% on the session, 10.0% below its 52-week high of $31.34 and 76% above its low of $16.00 — in the upper part of the range. Over the year it has ranged 96% from low to high: a wide band — moves of several percent in a week come with the territory. These are latest-session quotes, not live prices — the live tape is on the $ZYME page.
How much coverage it is getting
In the last 30 days Wook has filed 4 stories about $ZYME — 1 of them this week. At its 30-day pace you would expect about 1 a week, so this week is about normal. Across those stories the wording ran 0% bullish, 100% neutral and 0% bearish — mostly headline writers keeping a straight face. This one reads neutral, so it sits squarely with the crowd. 3 of the 4 (75%) came from Investing.com itself, so the count says as much about how often Investing.com hits publish as about how much attention there is — the other outlets are the better gauge. 12 of them are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$ZYME earnings in 12 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
The $ZYME page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $ZYME is from its high, or how this week's coverage compares.
How this analysis was made
Investing.com published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $ZYME. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.